OHOihane Uriarte Huarte

Oihane Uriarte Huarte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oihane Uriarte Huarte has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Locus coeruleus injury modulates ventral midbrain neuroinflammation during DSS-induced colitis

    by Jake Sondag Boles, Jenny Holt, Cassandra L. Cole, Noelle K. Neighbarger, Nikhil M. Urs, Oihane Uriarte Huarte, Malú Gámez Tansey

    Parkinson’s disease (PD) is characterized by a decades-long prodrome, consisting of a collection of non-motor symptoms that emerges prior to the motor manifestation of the disease. Of these non-motor symptoms, gastrointestinal dysfunction and deficits attributed to central norepinephrine (NE) loss, including mood changes and sleep disturbances, are frequent in the PD population and emerge early in the disease. Evidence is mounting that injury and inflammation in the gut and locus coeruleus (LC), respectively, underlie these symptoms, and the injury of these systems is central to the progression of PD. In this study, we generate a novel two-hit mouse model that captures both features, using dextran sulfate sodium (DSS) to induce gut inflammation and N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) to lesion the LC. We first confirmed the specificity of DSP-4 for central NE using neurochemical methods and fluorescence light-sheet microscopy of cleared tissue, and established that DSS-induced outcomes in the periphery, including weight loss, gross indices of gut injury and systemic inflammation, the loss of tight junction proteins in the colonic epithelium, and markers of colonic inflammation, were unaffected with DSP-4 pre-administration. We then measured alterations in neuroimmune gene expression in the ventral midbrain in response to DSS treatment alone as well as the extent to which prior LC injury modified this response. In this two-hit model we observed that DSS-induced colitis activates the expression of key cytokines and chemokines in the ventral midbrain only in the presence of LC injury and the typical DSS-associated neuroimmune is blunted by pre-LC lesioning with DSP-4. In all, this study supports the growing appreciation for the LC as neuroprotective against inflammation-induced brain injury and draws attention to the potential for NEergic interventions to exert disease-modifying effects under conditions where peripheral inflammation may compromise ventral midbrain dopaminergic neurons and increase the risk for development of PD.

  • Open Access

    Investigating the role of GPNMB in modulating LPS mediated inflammation in progranulin‐deficient macrophages

    by Drew A Gillett, Noelle Neighbarger, Oihane Uriarte Huarte, Malu Gámez Tansey

    Background: Progranulin (PGRN) is a glycosylated holoprotein that is critical to endo‐lysosomal health and regulating inflammatory responses over the lifespan. Insufficient PGRN due to nonsense mutations in the GRN gene has been linked to increased risk of developing Frontotemporal Dementia (FTD) and Neuronal Ceroid Lipofuscinosis (NCL‐11). The precise mechanism(s) behind the onset and progression of disease is unclear, and no disease‐modifying treatment exists. Previous work has identified increased glycoprotein non‐metastatic B (GPNMB) in both the cortex and plastma of Grn−/− mice relative to Grn+/+ mice, and our lab has recently identified different GPNMB expression in PGRN‐deficient immune cell populations, but it remains unclear how this increase in GPNMB modifies the inflammatory response(s) with PGRN deficits. This work seeks to investigate GPNMB expression over the course of the immune response in PGRN‐deficient cells, and the extent to which GPNMB modulates inflammation.Method: To investigate the role(s) of GPNMB in PGRN‐deficient myeloid cells, we isolated peritoneal macrophages (pMacs) from Grn+/+,and Grn−/− mice and quantified GPNMB protein before and after lipopolysaccharide (LPS) stimulation with western blot. We also determined the extent to which exposure to the GPNMB extracellular domain (ECD) modifies LPS‐elicited markers of inflammation in both Grn+/+and Grn−/‐ pMacs via qPCR. Finally, we determined how markers of inflammation were altered in pMacs from Grn−/−Gpmnb−/‐ relative to Grn+/+and Grn−/‐ with and without LPS stimulation.Result: We determined that the additional loss of GPNMB in Grn−/−Gpmnb−/− pMacs altered the expression of inflammatory markers after LPS challenge relative to both Grn−/−and Grn+/+ pMacs. We also discovered that GPNMB is dynamically regulated during and after LPS challenge in both Grn+/+ and Grn−/− pMacs. Finally, we determined that the addition of GPNMB ECD before and during LPS treatment ameliorated the altered expression of inflammatory markers during LPS challenge.Conclusion: The increase of GPNMB expression in Grn−/‐ myeloid cells is a significant modulator of inflammatory responses and may be a potential target in the development of therapeutics.

  • Open Access

    Microfluidics-free single-cell genomics reveals complex central-peripheral immune crosstalk in the mouse brain during peripheral inflammation

    by Jake Sondag Boles, Oihane Uriarte Huarte, Malú Gámez Tansey

    Inflammation is a realized detriment to brain health in a growing number of neurological diseases, but querying neuroinflammation in its cellular complexity remains a challenge. This manuscript aims to provide a reliable and accessible strategy for examining the brain’s immune system. We compare the efficacy of cell isolation methods in producing ample and pure immune samples from mouse brains. Then, with the high-input single-cell genomics platform PIPseq, we generate a rich neuroimmune dataset containing microglia and many peripheral immune populations. To demonstrate this strategy’s utility, we interrogate the well-established model of LPS-induced neuroinflammation with single-cell resolution. We demonstrate the activation of crosstalk between microglia and peripheral phagocytes and highlight the unique contributions of microglia and peripheral immune cells to neuroinflammation. Our approach enables the high-depth evaluation of inflammation in longstanding rodent models of neurological disease to reveal novel insight into the contributions of the immune system to brain health.


  • Open Access

    A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis

    by Jake Sondag Boles, Maeve E. Krueger, Janna E. Jernigan, Cassandra L. Cole, Noelle K. Neighbarger, Oihane Uriarte Huarte, Malú Gámez Tansey

    The gut and brain are increasingly linked in human disease, with neuropsychiatric conditions classically attributed to the brain showing an involvement of the intestine and inflammatory bowel diseases (IBDs) displaying an ever-expanding list of neurological comorbidities. To identify molecular systems that underpin this gut-brain connection and thus discover therapeutic targets, experimental models of gut dysfunction must be evaluated for brain effects. In the present study, we examine disturbances along the gut-brain axis in a widely used murine model of colitis, the dextran sodium sulfate (DSS) model, using high-throughput transcriptomics and an unbiased network analysis strategy coupled with standard biochemical outcome measures to achieve a comprehensive approach to identify key disease processes in both colon and brain. We examine the reproducibility of colitis induction with this model and its resulting genetic programs during different phases of disease, finding that DSS-induced colitis is largely reproducible with a few site-specific molecular features. We focus on the circulating immune system as the intermediary between the gut and brain, which exhibits an activation of pro-inflammatory innate immunity during colitis. Our unbiased transcriptomics analysis provides supporting evidence for immune activation in the brain during colitis, suggests that myelination may be a process vulnerable to increased intestinal permeability, and identifies a possible role for oxidative stress and brain oxygenation. Overall, we provide a comprehensive evaluation of multiple systems in a prevalent experimental model of intestinal permeability, which will inform future studies using this model and others, assist in the identification of druggable targets in the gut-brain axis, and contribute to our understanding of the concomitance of intestinal and neuropsychiatric dysfunction.


  • Open Access

    Concomitant AD and DLB pathologies shape subfield microglia responses in the hippocampus

    by Sonja Fixemer, Corrado Ameli, Gael P. Hammer, Luis M. Salamanca, Oihane Uriarte Huarte, Chantal Schwartz, Jean-Jacques Gérardy, Naguib Mechawar, Alexander Skupin, Michel Mittelbronn, et al.

    Hippocampal alteration is at the centre of memory decline in the most common age-related neurodegenerative diseases: Alzheimer’s disease (AD) and Dementia with Lewy Bodies (DLB). However, the subregional deterioration of the hippocampus differs between both diseases with more severe atrophy in the CA1 subfield of the AD patients. How AD and DLB-typical pathologies compose the various local microenvironment of the hippocampus across AD and DLB needs to be further explored to understand this process. Additionally, microglia responses could further impact the atrophy rate. Some studies suggest that microglia react differently according to the underlying neurodegenerative disorder. How microglia are transformed across hippocampal subfields in AD and DLB, and how their changes are associated with disease-typical pathologies remains to be determined. To these purposes, we performed a volumetric analysis of phospho-Tau (P-Tau), Amyloid-ß (Aß), and phospho-α-Synuclein (P-Syn) loads, quantified and classified microglia according to distinct morphological phenotypes using high-resolution confocal 3D microscopy of hippocampal CA1, CA3 and DG/CA4 subfields of late-onset AD (n=10) and DLB (n=8) as well as age-matched control samples (n=11). We found that each of the Tau, Aß and Synuclein pathologies followed a specific subregional distribution, relatively preserved across AD and DLB. P-Tau, Aß and P-Syn burdens were significantly exacerbated in AD, with Tau pathology being particularly severe in the AD CA1. P-Tau and P-Syn burdens were highly correlated across subfields and conditions (R2Spear = 0.79; P < 0.001) and result from a local co-distribution of P-Tau and P-Syn inclusions in neighbouring neurons, with only a low proportion of double-positive cells. In parallel, we assessed the changes of the microglia responses by measuring 16 morphological features of more than 35,000 individual microglial cells and classifying them into seven-distinct morphological clusters. We found microglia features- and clusters-variations subfield- and condition-dependent. Two of the seven morphological clusters, with more amoeboid and less branched forms, were identified as disease-enriched and found to be further increased in AD. Interestingly, some microglial features or clusters were associated with one but more often with a combination of two pathologies in a subfield-dependent manner. In conclusion, our study shows a multimodal association of the hippocampal microglia responses with the co-occurrence, distribution and severity of AD and DLB pathologies. In DLB hippocampi, pathological imprint and microglia responses follow AD trends but with lesser severity. Our study suggests that the increased pathological burdens of P-Tau and P-Syn and associated microglia alterations are involved in a more severe deterioration of the CA1 in AD as compared to DLB.